
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Primary Industry
Source
ALX Oncology
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: ALX Oncology was formerly known as Alexo Therapeutics Inc. The company is headquartered in Burlingame, California. ALX Oncology operates as a subsidiary of ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (NasdaqGS:ALXO)
Biotechnology
ALX Oncology Holdings Inc. (NasdaqGS:ALXO) 2021 Form 10-K
Business Description: ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company’s pre-clinical program focuses on the development of ALTA-002, a SIRPα TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
BeiGene, Ltd. (NasdaqGS:BGNE)
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Bristol-Myers Squibb Company (NYSE:BMY)
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Celgene Alpine Investment Co., LLC

Zymeworks Inc. (NasdaqGS:ZYME) 2021 Form 10-Q
Business Description: Celgene Alpine Investment Co., LLC operates as a subsidiary of Bristol-Myers Squibb Company.
Celgene Corporation
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. The company offers ABRAXANE, a paclitaxel powder for injectable suspension nanoparticle; IDHIFA that are enasidenib tablets; INREBIC, which are fedratinib capsules; ISTODAX, a lyophilized powder for injection; ONUREG that are azacitidine tablets; POMALYST, pomalidomide capsules; REBLOZYL, an injection for luspatercept; REVLIMID that are lenalidomide capsules; THALOMID, which are thalidomide capsules; VIDAZA, an injection of azacytidine; and ZEPOSIA that are ozanimod capsules. It provides pharmaceuticals in the areas of oncology, hematology, immunoscience, cardiovascular disease, and fibrosis. The company was incorporated in 1986 and is based in Summit, New Jersey. Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.
Daiichi Sankyo Company, Limited (TSE:4568)
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Eli Lilly and Company (NYSE:LLY)
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
GlaxoSmithKline Intellectual Property Development Limited
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: GlaxoSmithKline Intellectual Property Development Limited manufactures pharmaceutical drugs. The company was founded in 2012 and is based in Brentford, United Kingdom.GlaxoSmithKline Intellectual Property Development Limited operates as a subsidiary of Glaxosmithkline Intellectual Property Management Limited.
Iconic Therapeutics, Inc.
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California. As per the transaction announced on October 4, 2022, Iconic Therapeutics, Inc. operates as a subsidiary of Endpoint Health, Inc.
Janssen Biotech, Inc.
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Janssen Biotech, Inc., operates as a biopharmaceutical company, that specializes in the development and commercialization of therapeutic products for patients and the healthcare community. Its products are developed primarily through monoclonal antibody technology. The company has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the combination of the CD38-directed cytolytic antibody daratumumab and checkpoint inhibitor nivolumab in Phase 1b/Phase 2 clinical studies in multiple myeloma and various solid tumor types. It also has a research and commercialization agreement with Monash University for the early detection and prevention of rheumatoid arthritis, a debilitating autoimmune disease; and research collaboration and license agreement with Immune Biosolutions Inc. to discover and develop therapeutic antibodies in oncology. Janssen Biotech, Inc. has a research collaboration and licensing agreement with Teneobio, Inc. to develop multi-specific antibodies for undisclosed oncology targets; a research collaboration agreement with CHO Plus; a research collaboration and license agreement with Xencor, Inc. to discover novel CD28 bispecific antibodies for the treatment of prostate cancer, as well as with MacroGenics, Inc. to develop a preclinical bispecific molecule; a strategic collaboration with Revitope Oncology, Inc. to develop next-generation bi-specific antibody therapies; a research and development collaboration and option agreement with Genocea Biosciences, Inc., i2O Therapeutics, and BIOASIS TECHNOLOGIES INC. Janssen Biotech, Inc. was formerly known as Centocor Ortho Biotech, Inc. and changed its name to Janssen Biotech, Inc. in June 2011. The company was incorporated in 1979 and is based in Horsham, Pennsylvania. Janssen Biotech, Inc. operates as a subsidiary of Johnson & Johnson.
Jazz Pharmaceuticals plc (NasdaqGS:JAZZ)
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company’s lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
LEO Pharma A/S
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: LEO Pharma A/S, a research based pharmaceutical company, develops, manufactures, and markets pharmaceutical drugs for dermatologic and thrombotic patients. It focuses on drugs and therapies for the treatment of psoriasis, eczema, acne, and skin infections conditions that can cause serious physical and social discomfort. The company also provides products in the areas of thrombosis, cardiovascular, antibiotics, coagulation, osteoporosis, and renal care. It offers its products through its sales force in Denmark and internationally. LEO Pharma has collaboration with X-Chem, Inc. to discover and develop treatments for dermatological indications. The company was formerly known as Københavns Løveapoteks kemiske Fabrik and changed its name to LEO Pharma A/S in January 2002. The company was founded in 1908 and is based in Ballerup, Denmark with a location in Toronto, Canada. LEO Pharma A/S operates as a subsidiary of LEO Holding A/S.
Merck Sharp & Dohme Research GmbH
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2023 Form 10-K
Business Description: Merck Sharp & Dohme Research Gmbh researches and develops pharmaceutical preparations. The company is based in Lucerne, Switzerland. Merck Sharp & Dohme Research Gmbh operates as a subsidiary of Merck & Co., Inc.
Pfizer Inc. (NYSE:PFE)
Pharmaceuticals
Zymeworks Inc. (NasdaqGS:ZYME) 2022 Form 10-K
Business Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Seagen Inc. (NasdaqGS:SGEN)
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2022 Form 10-K
Business Description: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
*denotes proprietary relationship